The miracle balm of Gilead (A)
In 2013, US-based Gilead Sciences launched a miracle remedy for Hepatitis C. Sovaldi cured 90% of patients with a particular type of hepatitis in 12-weeks rather than the year it usually took, with greatly reduced side effects. Sovaldi generated great excitement worldwide. The only problem was its price. At $84,500 for a course of treatment, it was beyond the means of most patients. Advocacy groups had successfully won patent concessions from pharma companies including Gilead for HIV/AIDS treatments. Once again they launched major campaigns demanding that all patients be able to access this new drug based on need rather than ability to pay. Competitors, doctors, insurers, governments and patients all had their reasons to support the adoption of Sovaldi. The dynamics among these players would heavily impact Gilead’s future as well as the lives of millions of patients.
Understand the combined forces of stakeholders in exerting pressure on companies. Understand different health industry stakeholder motivations and agendas.
Gilead Sciences, Manufacturing, Biotechnology, Healthcare, Pharmaceuticals
2013-2014
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Officially, brands executives continue to display confidence that big luxury will shrug off the 2024 downturn as a cyclical one. They see it as the product of the combined collapse of real estate prices in China and a return to normalcy after the ...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 13 January 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 8 January 2025
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications